信邦制药8月29日获融资买入1297.87万元，融资余额2.83亿元

Core Viewpoint - The financial performance of Xinfang Pharmaceutical shows a decline in revenue and net profit, alongside notable changes in shareholder structure and financing activities [2][3]. Group 1: Financial Performance - For the first half of 2025, Xinfang Pharmaceutical reported a revenue of 2.845 billion yuan, a year-on-year decrease of 6.62% [2]. - The net profit attributable to shareholders for the same period was 107 million yuan, reflecting a year-on-year decline of 6.69% [2]. Group 2: Shareholder and Financing Activities - As of June 30, 2025, the number of shareholders for Xinfang Pharmaceutical was 66,700, a decrease of 0.41% from the previous period [2]. - The average circulating shares per person increased by 4.50% to 28,904 shares [2]. - On August 29, 2023, the financing buy-in amount was 12.98 million yuan, with a net buy of 590,700 yuan, indicating low financing balance at 283 million yuan, which is 4.01% of the circulating market value [1]. - The company has cumulatively distributed dividends of 706 million yuan since its A-share listing, with 345 million yuan distributed in the last three years [3]. Group 3: Stock Performance and Trading - On August 29, 2023, Xinfang Pharmaceutical's stock price fell by 1.36%, with a trading volume of 107 million yuan [1]. - The stock's short selling activity included a repayment of 300 shares and a sale of 2,300 shares, with a short selling balance of 102,440 yuan, indicating a higher level compared to the past year [1].